Araştırma Makalesi

Nöroblastoma hücrelerinde hesperidinin apoptozu tetiklemesi

Cilt: 3 Sayı: 3 30 Kasım 2018
PDF İndir
EN TR

Hesperidin triggering apoptosis on neuroblastoma cell

Abstract

Aim: Neuroblastoma accounts for approximately %10 of all pediatric cancers and approximately %15 of cancer related deaths in children. Understanding of the molecular mechanisms which play role in the progress of this cancer type may lead to develop more effective strategies for therapy. Flavanoids are popular subject for this new strategies. Hesperidin is an herbal flavonoid which is found abundantly in citrus that has been studied on several cancer cell lines. For this purpose, it was aimed to investigate is the apoptotic effects of hesperidin on neuroblastoma tumors using SH-SY5Y cell line.

Methods: Hesperidin was performed on SH-SY5Y and MRC-5 cell line by WST-1, Caspase-3 and Annexin V in a time and dose dependent manner.

Results: 2.5 µM hesperidin and 5 µM hesperidin were found the most suitable dosage for neuroblastoma cell line because of the success on decreasing cell proliferation. Hesperidin has resulted with the ability for apoptotic cell death compared with control group [MRC-5 cell line, p<0.05 for all]. 2,5 µM and 5 µM hesperidin concentration for 48h were ended up early apoptotic results as 53.65% for 2.5 µM and 38.90% for 5 µM. There was no significant change on caspase-3 activity.

Conclusions: Our study suggests that hesperidin would be effective against neuroblastoma tumors. We believe with further investigation this study will be helpful for developing new research areas in neuroblastoma tumors.

Keywords

Kaynakça

  1. 1. Ploessl C, Pan A, Maples KT, Lowe DK. Dinutuximab An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma. Ann Pharmacother. 2016;50:416-22.
  2. 2. London W, Castleberry RP, Matthay KK, Look AT, Seeger RC, Shimada H, et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol. 2005;23:6459-65.
  3. 3. Irwin MS, Park JR. Neuroblastoma: paradigm for precision medicine. Pediatr Clin North Am. 2015;62:225-56.
  4. 4. Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, et al. Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol. 2015;33:3008-17.
  5. 5. Schrey D, Vaidya SJ, Levine D, Pearson AD, Moreno L. Additional Therapies to Improve Metastatic Response to Induction Therapy in Children With High-risk Neuroblastoma. J Pediatr Hematol Oncol. 2015;37:e150-e153.
  6. 6. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. New Engl J Med. 1999;341:1165-73.
  7. 7. Keshelava N, Seeger RC, Groshen S, Reynolds CP. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res. 1998;58:5396-405.
  8. 8. Xiu LJ, Sun DZ, Jiao JP, Yan B, Qin ZF, Liu X et al. Anticancer effects of traditional Chinese herbs with phlegm-eliminating properties–An overview. J Ethnopharmacol. 2015;172:155-61.

Ayrıntılar

Birincil Dil

İngilizce

Konular

Klinik Tıp Bilimleri

Bölüm

Araştırma Makalesi

Yazarlar

Tolga Çatmakaş Bu kişi benim
Türkiye

Barış Ertuğrul Bu kişi benim
Türkiye

Yayımlanma Tarihi

30 Kasım 2018

Gönderilme Tarihi

30 Temmuz 2018

Kabul Tarihi

14 Eylül 2018

Yayımlandığı Sayı

Yıl 1970 Cilt: 3 Sayı: 3

Kaynak Göster

Vancouver
1.Tolga Çatmakaş, Barış Ertuğrul, Elif Sinem İplik, Bedia Çakmakoğlu. Hesperidin triggering apoptosis on neuroblastoma cell. Arch Clin Exp Med. 01 Kasım 2018;3(3):123-6. doi:10.25000/acem.449087

Cited By